Patents by Inventor Mehak Gupta

Mehak Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUM
    Publication number: 20240041772
    Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 8, 2024
    Inventors: Sonali Sandip Bharate, Vikas Kumar, Mehak Gupta, Sumit Ghandhi, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
  • Sustained release formulations of dysoxylum binefacterum
    Patent number: 11878075
    Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: January 23, 2024
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Sonali Sandip Bharate, Vikas Kumar, Mehak Gupta, Sumit Gandhi, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
  • Gastroretentive sustained release formulations of
    Patent number: 11446346
    Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: September 20, 2022
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sonali Sandip Bharate, Rohit Singh, Mehak Gupta, Bikarma Singh, Anil Kumar Katare, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
  • CELL-FREE PRODUCTION OF RIBONUCLEIC ACID
    Publication number: 20220064688
    Abstract: Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid.
    Type: Application
    Filed: March 15, 2021
    Publication date: March 3, 2022
    Applicant: GreenLight Biosciences, Inc.
    Inventors: William Jeremy Blake, Drew S. Cunningham, Daniel MacEachran, Mehak Gupta, James Robbins Abshire
  • METHODS AND COMPOSITIONS FOR NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID PRODUCTION
    Publication number: 20210309691
    Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.
    Type: Application
    Filed: November 10, 2020
    Publication date: October 7, 2021
    Applicant: GreenLight Biosciences, Inc.
    Inventors: Drew S. Cunningham, Daniel MacEachran, James Robbins Abshire, Himanshu Dhamankar, Ifeyinwa Iwuchukwu, Mehak Gupta, Matthew Eduardo Moura, Naveen Sudharsan, Nicholas Skizim, Rachit Jain, Karthikeyan Ramachandriya
  • SUSTAINED RELEASE FORMULATIONS OF DYSOXYLUM BINEFACTERUM
    Publication number: 20210137841
    Abstract: The present invention relates to the novel formulation for sustained or delayed release of rohitukine-rich Dysoxylum binectariferum extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract/fraction of rohitukine-rich Dysoxylum binectariferum with polymers has resulted in a sustained release of the extract or fraction over a period of 16-24 hrs. The said formulations are useful in the treatment of inflammatory diseases.
    Type: Application
    Filed: April 18, 2019
    Publication date: May 13, 2021
    Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Mehak GUPTA, Sumit GANDHI, Ajay KUMAR, Sandip Bibishan BHARATE, Ram VISHWAKARMA
  • Cell-free production of ribonucleic acid
    Patent number: 10954541
    Abstract: Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 23, 2021
    Assignee: GreenLight Biosciences, Inc.
    Inventors: William Jeremy Blake, Drew S. Cunningham, Daniel MacEachran, Mehak Gupta, James Robbins Abshire
  • SUSTAINED RELEASE FORMULATIONS OF CROCUS SATIVUS
    Publication number: 20200390843
    Abstract: The present invention is related to the novel oral dosage form for sustained release of crocin-1, a active constituent of Crocus sativus extract or fraction and a process for preparing the same wherein the extract is wet-granulated using excipients, biodegradable polymers and/or non-biodegradable polymers alone or in combination. The said formulations are useful for the treatment of chronic inflammatory diseases wherein NLRP3 inflammasome is involved.
    Type: Application
    Filed: October 18, 2018
    Publication date: December 17, 2020
    Inventors: Sonali Sandip BHARATE, Vikas KUMAR, Rohit SINGH, Sarita RANI, Mehak GUPTA, Ajay KUMAR, Sandip Bibishan BHARATE, Ram VISHWAKARMA
  • Methods and compositions for nucleoside triphosphate and ribonucleic acid production
    Patent number: 10858385
    Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: December 8, 2020
    Assignee: GreenLight Biosciences, Inc.
    Inventors: Drew S. Cunningham, Daniel MacEachran, James Robbins Abshire, Himanshu Dhamankar, Ifeyinwa Iwuchukwu, Mehak Gupta, Matthew Eduardo Moura, Naveen Sudharsan, Nicholas Skizim, Rachit Jain, Karthikeyan Ramachandriya
  • GASTRORETENTIVE SUSTAINED RELEASE FORMULATIONS OF BERGENIA CILIATA
    Publication number: 20200316150
    Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.
    Type: Application
    Filed: September 11, 2018
    Publication date: October 8, 2020
    Inventors: Sonali Sandip Bharate, Rohit Singh, Mehak Gupta, Bikarma Singh, Anil Kumar Katare, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
  • METHODS AND COMPOSITIONS FOR NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID PRODUCTION
    Publication number: 20190144489
    Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 16, 2019
    Applicant: GreenLight Biosciences, Inc.
    Inventors: Drew S. Cunningham, Daniel MacEachran, James Robbins Abshire, Himanshu Dhamankar, Ifeyinwa Iwuchukwu, Mehak Gupta, Matthew Eduardo Moura, Naveen Sudharsan, Nicholas Skizim, Rachit Jain, Karthikeyan Ramachandriya
  • CELL-FREE PRODUCTION OF RIBONUCLEIC ACID
    Publication number: 20170292138
    Abstract: Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: GreenLight Biosciences, Inc.
    Inventors: William Jeremy Blake, Drew S. Cunningham, Daniel MacEachran, Mehak Gupta, James Robbins Abshire